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Abstract 
Human tumor suppressor gene RIZ encodes two protein products, tumor suppressor RIZ1 
and proto-oncoprotein RIZ2, which regulate cellular functions in a Yin-Yang fashion. The only 
structural difference between them is that RIZ2 lacks the N-terminal PR domain. In this study, 
we showed that RIZ1 mRNA expression level was elevated in stage IV of eight different types 
of cancer (stage III for prostate cancer), indicating that RIZ1 might play an important role in 
tumor metastasis, and the PR domain alone possessed anticancer activity. 
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Introduction 
Yin-Yang regulation, which refers to dual com-
plimentary opposite reactions, has been discovered in 
many  biological  and  physiological  regulations.    Re-
cently, human tumor suppressor gene RIZ was shown 
to function in a Yin-Yang fashion [1, 2].  RIZ, located 
on the distal short arm of chromosome 1 (1p36), en-
codes two different protein products, RIZ1 and RIZ2, 
using  alternative  promoters  [1-10].    The  expression 
levels for RIZ1 and RIZ2 are nearly the same among 
many different human tissues except for the testes [9].  
RIZ2,  a  proto-oncoprotein,  promotes  cell  division; 
whereas RIZ1, a tumor suppressor, arrests cells in the 
G2/M phase of the cell cycle and induces apoptosis 
[10-12].    An  imbalance  in  the  amount  of  RIZ1  and 
RIZ2 may be an important cause of cancer develop-
ment [1].  In fact, silencing of RIZ1 expression, asso-
ciated with increased RIZ2 expression, has been ob-
served in various human cancers, such as hepatoma, 
leukemia, malignant lymphoma, breast cancer, colo-
rectal cancer, and thyroid carcinoma [1, 4-8, 13, 14]. 
RIZ1  and  RIZ2  share  identical  amino  acid  se-
quences  except  that  RIZ2  lacks  the  N-terminal  PR 
domain (PRDM2, ~200 amino acids) [9], which is  a 
member of the PRDM (PRDI-BF1 and RIZ homology 
domain) family [15].  Thus, the PR domain is possibly 
responsible  for  the  tumor  suppressing  activity  of 
RIZ1.  In vitro studies showed that PR interacted with 
a  PRB  (PR-binding)  motif  located  in  the  C-terminal 
region  of  both  RIZ1  and  RIZ2,  implicating  the 
Yin-Yang fashion between RIZ1 and RIZ2 in cell reg-
ulations [6, 16, 17].  Seventeen types of PRDMs have 
been identified in humans [15, 18].  Most of them are 
located  near  the  N-terminal  portion  of  the  proteins 
followed by zinc-fingers, and are involved in the reg-
ulation  of  cell  division  and  differentiation  [15,  18].  
PRDM1, PRDM2, PRDM3, PRDM4, PRDM5, PRDM14 
and  PRDM16,  which  have  been  identified  to  be  re-Int. J. Med. Sci. 2011, 8 
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lated  to  cancer,  are  also  functional  in  a  Yin-Yang 
fashion [2, 15, 18].  In addition, the PR domain was 
shown  to  possess  H3K9  histone  methyltransferase 
activity  [19].    Since  histone  methylation  has  been 
proposed  as  an  important  epigenetic  mechanism  to 
suppress cancer, the histone methyltransferase activ-
ity of the PR domain may as well play a critical role 
for the tumor suppressing function of RIZ1 [15]. 
Despite  recent  rapid  progress  in  RIZ1  studies, 
two important questions have not yet been addressed. 
The first question is whether the expression level for 
RIZ1 varies over the progression of cancer; and the 
second  question  is  whether  the  PR  domain  alone 
possesses anticancer activity.  In this study, we quan-
titatively  analyzed  the  mRNA  expression  level  of 
RIZ1 over the disease progression in eight different 
types of cancer, and evaluated the anticancer activity 
of  the  PR  domain  against  human  hepatoma  HuH7 
cells through both direct administration of recombi-
nant  His6-tagged  PR  and  cDNA  transfection.    Our 
results showed  that  the  PR domain alone exhibited 
anticancer activity. 
Materials and Methods 
Overexpression and purification of PR domain 
The cloning, overexpression and purification of 
recombinant  His6-tagget  PR  domain  has  been  pub-
lished previously [20]. 
Quantitative analysis of the RIZ1 mRNA expres-
sion level 
The protocol used to analyze mRNA expression 
levels  of  selected  target  genes  using  Origene  qPCR 
Cancer Survey Panels (Rockville, Maryland, USA) has 
been  reported  previously  [21].    Briefly,  the  primers 
and the TaqMan probe for gene RIZ encoding RIZ1 
were  designed  and  synthesized  by  Applied  Biosys-
tems (Carlsbad, California, USA) based on the inter-
nally  transcribed  spacer  (ITS)  region.    The  TaqMan 
probe  was  labeled  with  FAM  at  5’-end  and 
non-fluorescent quencher at 3’-end.  The RIZ1 mRNA 
expression levels were measured against the Origene 
TissueScan Cancer Survey Panel 96-I (twelve patients 
for each of the eight selected types of cancer) using 
quantitative RT-PCR on an Applied Biosystems 7300 
Real-Time PCR System. The RIZ1 mRNA expression 
was averaged in each disease stage and normalized to 
an  internal  control,  -actin.    The  fold-difference  in 
mRNA  expression  at  each  disease  stage  was  deter-
mined by comparison to expression levels in normal 
patients (stage 0, expression level set as 1).  Unpaired 
t-test  with  Welch’s  correction  between  the  RIZ1 
mRNA  expression  levels  in  normal  and  cancer  pa-
tients  for  each  cancer  type  was  performed  with 
GraphPad Prism 4.0 (GraphPad Software, San Diego, 
California, USA). 
Cell culture of HuH7 cell line 
Human hepatoma HuH7 were cultured in 6-well 
cell  culture  plates  in  Dulbecco’s  Modified  Eagle’s 
Medium with 10% fetal bovine serum and 1% gen-
tamicin in a humidified, 5% CO2 atmosphere at 37°C.  
The cell cultural media were changed every 2-3 days.  
The  HuH7  cells  were  subcultured  using  0.25% 
trypsin,  0.53  mM  EDTA  solution  before  reaching 
100% confluence. 
Anticancer activity of PR domain by direct ad-
ministration 
All  cell  line  experiments  were  undertaken  in 
triplicate.  The purified recombinant His6-tagged PR 
domain (> 90% purity) was directly administered into 
the cell cultural media with final concentrations of 1 
g/mL, 2  g/mL, and 3  g/mL, respectively, after 
the HuH7 cells reached 80-90% confluence.  Tris-HCl 
buffer was used as the blank control.  The cells were 
treated for 24 hr before the cell death rate was exam-
ined  by  the  trypan  blue  method.    The  cells  were 
stained  by  0.01%  trypan  blue  for  10  min  and  then 
examined under a microscope.  At least 100 cells were 
counted for each treatment.  Statistical analysis was 
performed  using  GraphPad  InStat  (GraphPad  Soft-
ware, San Diego, California, USA).  
Anticancer activity of PR domain by cDNA 
transfection 
The cloning of the PR domain (residues 13-193) 
has  been  reported  previously  [20].    Plasmid  DNA 
harvested from positively transformed Escherichia coli 
DH5 cells was digested by restriction endonucleases 
BamHI and XhoI.  The digested DNA fragment was 
subsequently  sub-cloned  into  the  expression  vector 
pcDNA/HisMax C (Invitrogen, Burlington, Ontario, 
Canada) at the BamHI and XhoI sites.  The constructed 
plasmid pcDNA/HisMax/PR vector was transfected 
into  HuH7  cells  (~  1  million)  by  the  calcium  phos-
phate  precipitation  method  [22].    Transfection  with 
the empty pcDNA/HisMax C vector was used as a 
control.  The expression of the PR domain in trans-
fected  HuH7  cells  was  confirmed  by  Western  blot 
described below; and the cell death rate was exam-
ined by the trypan blue method after 24 and 48 hr of 
transfections, respectively. 
Western blot of PR domain 
The expression of the PR domain was examined 
after 24 hr of transfection with pcDNA/HisMax/PR 
and the empty vector, respectively.  Supernatants (30 
g) of the cell lysates were separated by SDS-PAGE Int. J. Med. Sci. 2011, 8 
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and transferred onto nitrocellulose membranes. The 
membranes were incubated with anti-Histidine tag or 
anti-β-actin antibodies overnight at 4 °C before being 
blotted  with  anti-rabbit  IgG  conjugated  with  horse-
radish peroxidase (1: 3000), for 1 hr at room temper-
ature.    The  blotting  results  were  scanned  using  a 
Li-Cor Odyssey scanner (Li-Cor, Lincoln, Nebraska, 
USA).  
 
Results and Discussion 
RIZ1 mRNA expression 
The RIZ1 mRNA expression level was elevated 
by an average of 3.1 fold in breast cancer (P=0.006) 
and decreased by 2 fold in thyroid cancer (P=0.028), 
respectively  (Table  1).    The  change  in  RIZ1  mRNA 
expression  was  not  statistically  significant  in  colon, 
kidney, liver, lung, ovarian and prostate cancers.  To 
obtain a preliminary impression on whether the ex-
pression of RIZ1 varies with cancer progression, we 
first compared the RIZ1 mRNA expression levels in 
late  stages  (III  and  IV  combined)  versus  the  early 
stages (I and II combined).  No statistically significant 
variation was observed for any type of cancer (P value 
ranging from 0.35 to 0.94).  Then, we compared the 
RIZ1 mRNA expression level at each individual can-
cer stage (Fig. 1), however, the small sample size as-
sociated with the panel (n=12 for each cancer type) 
precluded a complete analysis, one that must await a 
larger scale screening study.  Nonetheless, we have 
gleaned valuable information from our limited analy-
sis, which will provide an important reference for the 
design of future screenings.  
 
 
 
Table 1. The average fold difference (FD) in RIZ1 mRNA 
expression level in patients with cancer relative to patients 
without cancer 
Cancer Type  FD  P-value 
Breast  3.1  0.006 
Colon  1.1  0.976 
Kidney  0.6  0.070 
Liver  0.8  0.384 
Lung  1.3  0.768 
Ovary  1.9  0.615 
Prostate  0.7  0.351 
Thyroid  0.5  0.028 
 
 
The most interesting discovery was that the RIZ1 
mRNA expression was increased by 22.1, 4.2, 1.8, 2.4, 
2.7, 1.4 and 4.7 folds at stage IV in breast, colon, kid-
ney, liver, lung, ovarian and thyroid cancers, respec-
tively, and 4.8 folds at stage III in prostate cancer (Fig. 
1).  Because cancer undergoes metastasis and spreads 
to other organs at late stages, we speculated that RIZ1 
might  play  an  important  role  in  tumor  metastasis, 
although  increases  in  mRNA  expression  do  not  al-
ways translate proportionally into protein expression 
levels.  Our speculation was in line with two previous 
observations [23, 24].   
The first observation was that RIZ1 up-regulates 
insulin-like growth factor-binding protein 2 (IGFBP2) 
and secreted glycoprotein  SPARC (secreted protein, 
acidic  and  rich  in  cysteine)  [23],  both  of  which  are 
highly  expressed  in  malignant  tissues  and  promote 
tumor metastasis [25-28].  The second observation was 
that  RIZ1  may  augment  the  expression  of  nuclear 
factor of activated T cell 1 (NFATc1) [24], which in-
duces breast cancer cell invasion via cyclooxygenase-2 
[29].      Therefore,  we  hypothesize  that  RIZ1  might 
possess  dual  functions  during  tumor  progression, 
acting as a tumor suppressor to induce apoptosis in 
the early stages and a tumor promoter to induce me-
tastasis in late stages.  If this hypothesis were proved 
valid, the net result of RIZ1’s apparently conflicting 
function at early and late stages of cancer would be 
decreasing local cancer cell population, an apparently 
unsuccessful  self-protective  mechanism  of  human 
body in battling against cancer.  Further characteriza-
tion including metastatic studies is needed to prove 
this hypothesis.   
Moreover,  we  observed  amino  acid  sequence 
similarities in three regions between RIZ1 and ephrin 
receptor  (EphR)  during  sequence  analysis  (Fig.  2).  
The sequence identity and homology were 34.2% and 
68.4%, 37.0% and 81.5%, and 22.9% and 53.1% in the 
three aligned regions, respectively (Fig. 2).  In EphR, 
residues 63-99 are located in a region responsible for 
extracellular ligand binding, residues 771-802 are lo-
cated in a region responsible for intracellular tyrosine 
kinase activity, and residues 924-973 are located in an 
essential motif for dimerization of receptor tyrosine 
kinases  [30].    Since  EphR  is  often  overexpressed  in 
cancer and involved in metastasis [31, 32], it is defi-
nitely worth further exploration on whether overex-
pression  of  RIZ1  could  produce  any  effect  on  the 
ephrin signalling pathways. Int. J. Med. Sci. 2011, 8 
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Fig. 1. Relative fold-difference in RIZ1 mRNA expression at different disease stages of human breast (A), colon (B), kidney 
(C), liver (D), lung (E), ovary (F), prostate (G) and thyroid (H) cancers. RIZ1 mRNA expression was screened in the Origene 
TissueScan  Cancer  Survey  Panel  96-I  and  normalized  to  the  internal  control,  β-actin  in  the  different  patients.  The 
fold-difference in mRNA expression at each disease stage was determined by comparison to expression levels in normal 
patients (stage 0, expression level set as 1). Int. J. Med. Sci. 2011, 8 
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Fig. 2. Amino acid sequence alignment between RIZ1 and ephrin receptor (EphR) in the extracellular ligand binding region, 
residues 63-99 (A), the intracellular tyrosine kinase region, residues 771-802 (B), and the essential motif for dimerization of 
receptor tyrosine kinases, residues 924-973 (C). Identical and homologous residues are shown in red and blue, respectively.  
The sequence identity and homology between RIZ1 and EphR were 34.2% and 68.4% in the residues 63-99 region, 37.0% and 
81.5% in the residues 771-802 region, and 22.9% and 53.1% in the residues 924-973 region, respectively. 
 
The second interesting observation in this study 
was that the RIZ1 mRNA expression is elevated in all 
stages through the progression of breast cancer (Fig. 
1A).  This is in contrary to the previous studies that 
RIZ1  was  under-expressed  in  breast  cancer  [4].  
However, the current result is consistent with a study 
on cancer stem cells that only 11-35% breast cancer 
cells  sustained  tumor  growth  through  cell  division 
[33], implicating that RIZ1 was likely overexpressed 
and  acted  as  a  tumor  suppressor  to  inhibit  breast 
cancer cell growth during disease progression.  As for 
the other types of cancer, the RIZ1 mRNA level was 
down-regulated  from  stage  I  to  III  (except  prostate 
cancer), which is consistent with the previous studies 
[1, 5-8].  Since either stage III of colon cancer or stage 
IIB of ovarian cancer has only one elderly patient (80 
years and older), the RIZ1 mRNA expression increase 
may not be necessarily representative for the disease 
stage. 
Anticancer activity of PR Domain 
Transfection  with  full-length  RIZ1  has  been 
shown  to  suppress  cancer  cell  growth  in  hepatoma 
and chronic myeloid leukemia [11, 23].  Since PR do-
main is the only structural difference between the two 
protein  products  (RIZ1  and  RIZ2)  of  gene  RIZ,  we 
decided  to  examine  whether  the  PR  domain  alone 
possessed any anticancer activity.  Initially, we added 
purified  His6-tagged  PR  domain  (>90%  purity)  di-
rectly  to  the  cultural  media  for  human  hepatoma 
HuH7 cells.  The PR domain slightly increased the cell 
death rate for HuH7 cells at all three tested PR do-
main concentrations (Fig. 3A).   Statistical significance 
was observed for the 1 µg/mL treatment (P=0.030), 
however,  the  increase  in  cell  death  rate  was  only 
marginal (< 2.5%).  This indicated that it was unlikely 
that a receptor or transporter is present on the HuH7 
cell membrane to actively mediate the translocation of 
PR domain into the cells. 
To ensure the presence of PR domain within the 
cells,  we  transfected  HuH7  cells  with  a  plasmid 
(pcDNA/HisMax/PR)  expressing  the  PR  domain.  
The PR domain expression was examined by Western 
blot  after  24  hr  of  transfection  using  β-actin  as  a 
loading control.  As shown in Fig. 3C, the PR domain 
was expressed in the HuH7 cells transfected with the 
pcDNA/HisMax/PR  vector  but  not  in  the  cells 
transfected with the empty pcDNA/HisMax C vector.  
The cell death rate for HuH7 cells was measured at 24 
and 48 hr, respectively, after transfection.  As shown 
in Fig. 3B, the cell death rate was increased from 17% 
to 48% after 24 hr of transfection and from 24% to 74% 
after 48 hr of transfection.  Because either recombinant 
His6-tagged or GST-tagged PR domain is well folded 
in both prokaryotic Escherichia coli [20] and eukaryotic 
yeast cells (unpublished data), it is unlikely that the 
increased cell death was due to improper folding of Int. J. Med. Sci. 2011, 8 
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RIZ1 in the tranfected HuH7 cells.  Thus, the above 
observation suggested that the PR domain alone pos-
sesses anticancer activity.  However, it is still unclear 
whether the anticancer activity of the PR domain is 
due to its methyltransferase activity or the interaction 
with the PRB motif.  Further studies with a methyl-
transferase inhibitor specific for the PR domain may 
help to understand the exact mechanism for its anti-
cancer function. 
 
 
 
 
Fig. 3. Anticancer activity of the PR domain against human hepatocarcinoma HuH7 cells either by direct admission (A) or 
transfection (B).  The PR domain concentrations were 1 g/mL, 2 g/mL, and 3 g/mL, respectively, in the direct admin-
istration.  The cell death rate was measured by the trypan blue method. For the transfection, the HuH7 cells were trans-
fected with the constructed viral vector pcDNA/HisMax/PR encoding the PR domain (shown in green) and the empty viral 
vector pcDNA/HisMax as a control (shown in blue). The cell death rate was also measured by the trypan blue method after 
24 and 48 hr of transfection, respectively. The PR domain expression in the transfected HuH7 cells was confirmed by 
Western blot after 24 hr of transfection (C). 
 
Conclusion 
In  this  study,  RIZ1  mRNA  expression  was 
shown to be up-regulated in stage IV of eight types of 
cancer  (stage  III  in  prostate  cancer),  indicating  that 
RIZ1 might play an important role in tumor metasta-
sis in late disease stages in addition to the previously 
reported tumor suppressor activity. The PR domain of 
RIZ1 possessed anticancer activity from the transfec-
tion  studies.    This  finding  leaves  us  an  important 
question on the roles the other structural components 
of RIZ1 in its anticancer function. 
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